-
公开(公告)号：US11926619B2
公开(公告)日：2024-03-12
申请号：US17045952
申请日：2019-04-08
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Gregg F. Keaney , John Wang , Baudouin Gerard , Kenzo Arai , Xiang Liu , Guo Zhu Zheng , Kazunobu Kira , Lisa A. Marcaurelle , Marta Nevalainen , Ming-Hong Hao , Morgan Welzel O'Shea , Parcharee Tivitmahaisoon , Sudeep Prajapati , Tuoping Luo , Nicholas C. Gearhart , Jason T. Lowe , Yoshihiko Kotake , Satoshi Nagao , Regina Mikie Kanada Sonobe , Masayuki Miyano , Norio Murai , Andrew Cook , Shelby Ellery , Atsushi Endo , James Palacino , Dominic Reynolds
IPC: C07D407/12 , A61K31/365 , A61K31/4427 , A61K31/497 , A61K45/06 , A61P35/00 , C07D313/00 , C07D405/12 , C07D405/14 , C07D407/06 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/08 , C07D487/10 , C07D491/107
CPC classification number: C07D407/06 , A61K45/06 , A61P35/00 , C07D313/00 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/08 , C07D487/10 , C07D491/107
Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
-
公开(公告)号：US11679107B2
公开(公告)日：2023-06-20
申请号：US17046528
申请日：2019-04-11
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Andrew Cook , Dominic Reynolds , Cheng Zhong , Ryan Brawn , Shelby Ellery , Thiwanka Samarakoon , Xiang Liu , Sudeep Prajapati , Megan Sheehan , Jason T. Lowe , James Palacino
IPC: C07D405/06 , A61K31/496 , A61P35/00 , A61K9/00 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/395 , C07D313/00 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08
CPC classification number: A61K31/496 , A61K9/0053 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/191 , A61K38/208 , A61K38/2013 , A61K38/2066 , A61K38/2086 , A61K38/217 , A61K39/3955 , A61P35/00 , C07D313/00 , C07D405/06 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08 , C07B2200/05
Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy
